About crizotinib
ALK and ROS1 tyrosine kinase inhibitor
Used for
- Certain ALK-positive non-small-cell lung cancers
- Certain ROS1-positive non-small-cell lung cancers
- ALK-positive systemic anaplastic large cell lymphoma in children
- ALK-positive inflammatory myofibroblastic tumors in children
Usual adult dose
250 mg by mouth twice daily for lung cancer; dose adjustments may be needed.
Usual dose in children
For eligible cancers, dosing is based on body surface area, usually twice daily; specialist-directed.
Common side effects
- Vision changes
- Nausea, diarrhea, vomiting, or constipation
- Swelling, tiredness, or dizziness
- Abnormal liver tests
Important warnings
- Can cause serious liver injury; liver tests need monitoring.
- Can cause slow heart rate or changes in heart rhythm.
- Vision problems can occur; report sudden or worsening changes.
- Rarely causes lung inflammation; new breathing symptoms need prompt assessment.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 45 days after the last dose.
Breastfeeding
Do not breastfeed during treatment and for 45 days after the last dose.
Interactions
- Strong CYP3A inhibitors can raise crizotinib levels.
- Strong CYP3A inducers can lower crizotinib levels.
- Crizotinib can raise levels of some medicines, including certain statins and heart medicines.
- Medicines that prolong the QT interval may increase heart-rhythm risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.